Health Trials

About this trial

Mild Autonomous Cortisol Secretion (MACS) is a condition in which an adrenal gland produces excess cortisol and is associated with high blood pressure, diabetes, and weight gain. Surgical removal of the adrenal gland (adrenalectomy) is standard treatment, but some patients continue to have metabolic health problems after surgery.

This randomized study will evaluate whether treatment with tirzepatide after adrenalectomy improves metabolic outcomes in patients with MACS compared with adrenalectomy alone.

Eligibility criteria

Qualifiers

Adults aged 18 years and older

Diagnosis of MACS, defined as morning cortisol >1.8 mcg/dL after a 1 mg dexamethasone suppression test

Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2025 American College of Cardiology/American Heart Association [ACC/AHA] criteria, or current use of antihypertensive medication)

BMI ≥27

Disqualifiers

Bilateral adrenal lesions

Adrenal malignancy

Concurrent primary aldosteronism with MACS

Current use of GLP-1 receptor agonists

Trial design

Treatments tested in this trial

  • Tirzepatide
  • Standard medical treatment

Treatment groups

34 Participants
are divided into 2 treatment groups

Locations

1
University of Pittsburgh Medical Center15213, PittsburghPennsylvania, United States

Sponsors and collaborators

Alaa Sada

Lead sponsor

University of Pittsburgh

Sponsor institution

Source ClinicalTrials.gov